Mei Pharma Stock Today
| MEIP Stock | USD 2.81 0.01 0.36% |
Performance0 of 100
| Odds Of DistressOver 79
|
MEI Pharma is selling at 2.81 as of the 21st of November 2024; that is 0.36 percent increase since the beginning of the trading day. The stock's last reported lowest price was 2.77. MEI Pharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for MEI Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of December 2003 | Category Healthcare | Classification Health Care |
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Mei Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.66 M outstanding shares of which 80.97 K shares are now shorted by private and institutional investors with about 0.94 trading days to cover. More on MEI Pharma
Moving together with MEI Stock
Moving against MEI Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
MEI Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and President and Director | Daniel Gold | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMEI Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand MEI Pharma's financial leverage. It provides some insight into what part of MEI Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
MEI Pharma (MEIP) is traded on NASDAQ Exchange in USA. It is located in 9920 Pacific Heights Blvd., San Diego, CA, United States, 92121 and employs 28 people. MEI Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 18.66 M. MEI Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.66 M outstanding shares of which 80.97 K shares are now shorted by private and institutional investors with about 0.94 trading days to cover.
MEI Pharma currently holds about 153.25 M in cash with (50.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15.
Check MEI Pharma Probability Of Bankruptcy
Ownership AllocationThe market capitalization of MEI Pharma is $18.66 Million. 30% of MEI Pharma outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Thus, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
Check MEI Ownership Details
MEI Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Squarepoint Ops Llc | 2024-06-30 | 17.5 K | |
| Citadel Advisors Llc | 2024-06-30 | 15.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 11.7 K | |
| Susquehanna International Group, Llp | 2024-06-30 | 10.3 K | |
| Ubs Group Ag | 2024-06-30 | 8.1 K | |
| Tower Research Capital Llc | 2024-06-30 | 3.8 K | |
| Group One Trading, Lp | 2024-06-30 | 2.8 K | |
| Newbridge Financial Services Group, Inc. | 2024-06-30 | 2 K | |
| Fmr Inc | 2024-09-30 | 1000 | |
| Anson Funds Management Lp | 2024-06-30 | 1.1 M | |
| Cable Car Capital Llc | 2024-06-30 | 611.4 K |
MEI Pharma Historical Income Statement
MEI Stock Against Markets
MEI Pharma Corporate Management
| BA Esq | COO Counsel | Profile | |
| Anne Frese | Chief Officer | Profile | |
| Eugene Park | VP Marketing | Profile | |
| Virginia Sankey | VP Fin | Profile | |
| JD Esq | Chief Officer | Profile | |
| Eric Deng | VP Operations | Profile | |
| Richard Ghalie | Chief Officer | Profile |
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.